INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1601, 28087, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1602, 28088, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1603, 4454, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1604, 4455, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1605, 4457, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1606, 5419, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1607, 6347, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1608, 6352, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1609, 6353, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1610, 9544, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1611, 9545, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1612, 9554, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1613, 11212, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1614, 14273, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1615, 14274, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1616, 14275, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1617, 19674, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1618, 20879, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1619, 20880, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1620, 20881, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1621, 20882, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1622, 24438, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1623, 24440, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1624, 24441, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1625, 24442, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1626, 24443, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1627, 24445, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1628, 24446, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1629, 24447, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1630, 24448, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1631, 24460, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1632, 24461, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1633, 27945, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1634, 28761, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1635, 28762, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1636, 28763, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1637, 28764, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1638, 33367, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1639, 33368, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1640, 33369, 'Paclitaxel (protein-bound)', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme.  Current data suggest that consumption of large quantities of grapefruit juice inhibit both intestinal and hepatic CYP450 3A4 due to certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1641, 4454, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1642, 4455, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1643, 4457, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1644, 5419, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1645, 6347, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1646, 6352, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1647, 6353, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1648, 9544, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1649, 9545, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1650, 9554, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1651, 11212, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1652, 14273, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1653, 14274, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1654, 14275, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1655, 19674, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1656, 20879, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1657, 20880, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1658, 20881, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1659, 20882, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1660, 24438, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1661, 24440, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1662, 24441, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1663, 24442, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1664, 24443, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1665, 24445, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1666, 24446, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1667, 24447, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1668, 24448, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1669, 24460, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1670, 24461, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1671, 27945, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1672, 28761, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1673, 28762, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1674, 28763, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1675, 28764, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1676, 33367, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1677, 33368, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1678, 33369, 'Paclitaxel', 'Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme', 'grapefruit juice', 'Moderate', 'Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice.  Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1679, 2994, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1680, 3521, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1681, 3522, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1682, 3762, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1683, 11969, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1684, 11970, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1685, 17403, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1686, 17404, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1687, 17916, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1688, 17918, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1689, 17919, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1690, 18577, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1691, 24407, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1692, 24408, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1693, 24409, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1694, 28854, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1695, 31540, 'Oxybutynin', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.  No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1696, 6545, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1697, 20914, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1698, 20916, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1699, 20917, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1700, 20918, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1701, 24464, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1702, 24465, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1703, 24747, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1704, 28443, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1705, 28444, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1706, 28445, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1707, 28446, 'Paliperidone', 'Alcohol may potentiate some of the pharmacologic effects of paliperidone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving paliperidone should be advised to avoid the consumption of alcohol.  Since clinical trials establishing the safety and efficacy of paliperidone were carried out without regard to the timing of meals, presumably paliperidone may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1708, 24417, 'Oxycodone', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone.  Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1709, 24418, 'Oxycodone', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone.  Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1710, 24419, 'Oxycodone', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone.  Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1711, 24420, 'Oxycodone', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone.  Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1712, 0, 'Panobinostat', 'Grapefruit juice may increase the plasma concentrations of panobinostat.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients should avoid consumption of grapefruit or grapefruit juice during treatment with panobinostat.  The manufacturer also recommends avoiding star fruit, Seville oranges, pomegranate, and pomegranate juice.  Panobinostat may be administered with or without food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1713, 9657, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1714, 9669, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1715, 10366, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1716, 10367, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1717, 17265, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1718, 24597, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1719, 24598, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1720, 24601, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1721, 24602, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1722, 24603, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1723, 33383, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1724, 33384, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1725, 33385, 'Paroxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1726, 0, 'Pegaspargase', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury.  Asparaginase-associated hepatotoxicity has been reported more commonly in adults than in children and has been strongly associated with obesity.  Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults.  Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.  ', 'alcohol', 'Moderate', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins).  Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs.  Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1727, 0, 'Patiromer', 'Patiromer can bind to some orally administered drugs, which may decrease their gastrointestinal absorption and reduce their effectiveness', 'food', 'Moderate', 'Patiromer should be administered with food at least 3 hours before or 3 hours after other oral medications.  Alternatives to patiromer or the other medications should be considered if adequate dosing separation is not possible.  Otherwise, clinical response and/or blood levels should be monitored where possible.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1728, 0, 'Acetaminophen', 'Chronic, excessive consumption of alcohol may increase the risk of acetaminophen-induced hepatotoxicity, which has included rare cases of fatal hepatitis and frank hepatic failure requiring liver transplantation.  The proposed mechanism is induction of hepatic microsomal enzymes during chronic alcohol use, which may result in accelerated metabolism of acetaminophen and increased production of potentially hepatotoxic metabolites.', 'alcohol', 'Major', 'In general, chronic alcoholics should avoid regular or excessive use of acetaminophen.  Alternative analgesic/antipyretic therapy may be appropriate in patients who consume three or more alcoholic drinks per day.  However, if acetaminophen is used, these patients should be cautioned not to exceed the recommended dosage (maximum 4 g/day in adults and children 12 years of age or older).', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1729, 14520, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1730, 14521, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1731, 14522, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1732, 14655, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1733, 14656, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1734, 14657, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1735, 18005, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1736, 18518, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1737, 18523, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1738, 18524, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1739, 18525, 'Avanafil', 'Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators.', 'alcohol', 'Moderate', 'Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.  It may also be appropriate to avoid consuming large amounts of grapefruit juice.  Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1740, 0, 'Penbutolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1741, 0, 'Pemigatinib', 'Grapefruit juice may increase the plasma concentrations of pemigatinib, which is primarily metabolized by CYP450 3A4 in vitro.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.', 'grapefruit juice', 'Major', 'Pemigatinib may be administered with or without food.  Patients should avoid consumption of grapefruit, grapefruit juice, or supplements that contain grapefruit extract during treatment with pemigatinib.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1742, 14775, 'Peginterferon beta-1a', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal.  The dosage may be gradually re-escalated when enzyme levels return to normal.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1743, 25748, 'Peginterferon beta-1a', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal.  The dosage may be gradually re-escalated when enzyme levels return to normal.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1744, 25749, 'Peginterferon beta-1a', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal.  The dosage may be gradually re-escalated when enzyme levels return to normal.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1745, 25750, 'Peginterferon beta-1a', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal.  The dosage may be gradually re-escalated when enzyme levels return to normal.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1746, 0, 'Pentazocine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1747, 0, 'Pentazocine', 'Smoking tobacco may decrease the plasma concentrations and effects of pentazocine by enhancing its metabolic clearance.', 'cigarette', 'Moderate', 'The possibility of reduced therapeutic effects of pentazocine should be considered in smokers.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1748, 16931, 'Penicillamine', 'Food may interfere with the gastrointestinal absorption of penicillamine.', 'food', 'Moderate', 'Penicillamine should be administered on an empty stomach, at least one hour before or two hours after meals, and at least one hour apart from any other drug, food, or milk.  This permits maximum absorption and reduces the likelihood of inactivation by metal binding in the gastrointestinal tract.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1749, 25939, 'Penicillamine', 'Food may interfere with the gastrointestinal absorption of penicillamine.', 'food', 'Moderate', 'Penicillamine should be administered on an empty stomach, at least one hour before or two hours after meals, and at least one hour apart from any other drug, food, or milk.  This permits maximum absorption and reduces the likelihood of inactivation by metal binding in the gastrointestinal tract.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1750, 0, 'Perampanel', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1751, 0, 'Pentobarbital', 'Concurrent acute use of barbiturates and ethanol may result in additive CNS effects,  including impaired coordination, sedation, and death.  Tolerance of these agents may occur with chronic use.  The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.', 'alcohol', 'Major', 'The combination of ethanol and barbiturates should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1752, 0, 'Pergolide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1753, 0, 'Avatrombopag', 'Food reduces the variability in oral absorption and bioavailability of avatrombopag.  According to the product labeling, avatrombopag peak plasma concentration (Cmax) and systemic exposure (AUC) were not affected when administered with either a low-fat (500 calories; 3 g fat, 15 g proteins, 108 g carbohydrates) or high-fat (918 calories; 59 g fat, 39 g proteins, 59 g carbohydrates) meal.  However, the variability of avatrombopag exposure was reduced by 40% to 60% with food, and the time to reach Cmax was delayed by 0 to 2 hours relative to the fasted state.', 'high-fat foods', 'Moderate', 'To ensure consistent absorption and plasma drug levels, avatrombopag should be taken with food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1754, 11667, 'Perphenazine', 'Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during phenothiazine therapy.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1755, 28506, 'Perphenazine', 'Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during phenothiazine therapy.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1756, 28507, 'Perphenazine', 'Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during phenothiazine therapy.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1757, 29604, 'Pazopanib', 'Grapefruit juice may increase the plasma concentrations of pazopanib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with pazopanib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  Pazopanib should be administered at least one hour before or two hours after a meal.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1758, 29605, 'Pazopanib', 'Grapefruit juice may increase the plasma concentrations of pazopanib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with pazopanib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  Pazopanib should be administered at least one hour before or two hours after a meal.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1759, 206, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1760, 3125, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1761, 8994, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1762, 16875, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1763, 16876, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1764, 16877, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1765, 25414, 'Perindopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1766, 206, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1767, 3125, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1768, 8994, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1769, 16875, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1770, 16876, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1771, 16877, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1772, 25414, 'Perindopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1773, 0, 'Avapritinib', 'Grapefruit juice may increase the plasma concentrations of avapritinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.', 'grapefruit juice', 'Major', 'Avapritinib should be administered on an empty stomach at least 1 hour before or 2 hours after a meal.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with avapritinib.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1774, 0, 'Pexidartinib', 'Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib.  Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury.', 'alcohol', 'Major', 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided.  Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter.  Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity.  A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib.  Liver function tests should be performed weekly for the first month after rechallenge.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1775, 0, 'Pexidartinib', 'The presence of food may increase the absorption and toxicity of pexidartinib.  Administration of pexidartinib with a high-fat meal increased peak plasma concentration (Cmax) and systemic exposure (AUC) by 100% and prolonged the time to reach peak plasma concentration (Tmax) by 2.5 hours.', 'high-fat foods', 'Major', 'Pexidartinib should be administered on an empty stomach, at least one hour before or two hours after a meal or snack.  Consumption of grapefruit or grapefruit juice should generally be avoided during pexidartinib therapy.  If concomitant use is unavoidable, the dose of pexidartinib should be reduced according to the manufacturer''s recommendations.  If concomitant use of grapefruit or grapefruit juice is discontinued, the dose of pexidartinib may be increased (after 3 plasma half-lives of a strong CYP450 3A4 inhibitor) to the dose that was used prior to consumption of grapefruit or grapefruit juice.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1776, 0, 'Pexidartinib', 'The presence of food may increase the absorption and toxicity of pexidartinib.  Administration of pexidartinib with a high-fat meal increased peak plasma concentration (Cmax) and systemic exposure (AUC) by 100% and prolonged the time to reach peak plasma concentration (Tmax) by 2.5 hours.', 'grapefruit juice', 'Major', 'Pexidartinib should be administered on an empty stomach, at least one hour before or two hours after a meal or snack.  Consumption of grapefruit or grapefruit juice should generally be avoided during pexidartinib therapy.  If concomitant use is unavoidable, the dose of pexidartinib should be reduced according to the manufacturer''s recommendations.  If concomitant use of grapefruit or grapefruit juice is discontinued, the dose of pexidartinib may be increased (after 3 plasma half-lives of a strong CYP450 3A4 inhibitor) to the dose that was used prior to consumption of grapefruit or grapefruit juice.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1777, 3826, 'Phenobarbital', 'Concurrent acute use of barbiturates and ethanol may result in additive CNS effects,  including impaired coordination, sedation, and death.  Tolerance of these agents may occur with chronic use.  The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.', 'alcohol', 'Major', 'The combination of ethanol and barbiturates should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1778, 0, 'Phenelzine', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1779, 24890, 'Phenylbutyric acid', 'Coadministration with a high-fat meal may reduce the rate and extent of absorption of sodium phenylbutyrate.', 'high-fat foods', 'Moderate', 'The prescribing information recommends administration of sodium phenylbutyrate-taurursodiol before a meal or snack, particularly in patients of low body weight (less than 70 kg).', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1780, 0, 'Phenoxybenzamine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1781, 26249, 'Phentolamine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1782, 26250, 'Phentolamine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1783, 0, 'Phentermine', 'Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants.', 'alcohol', 'Moderate', 'Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease.  Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1784, 0, 'Phendimetrazine', 'Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants.', 'alcohol', 'Moderate', 'Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease.  Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1785, 2177, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1786, 5954, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1787, 18352, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1788, 18425, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1789, 20272, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1790, 20929, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1791, 20930, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1792, 20931, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1793, 24859, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1794, 24872, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1795, 24875, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1796, 24876, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1797, 24877, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1798, 24878, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1799, 24879, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1800, 24880, 'Phenytoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'food', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', '', '', 'DDInter', 0);